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VEGFR2 pY949 signalling regulates adherens
junction integrity and metastatic spread
Xiujuan Li1,*, Narendra Padhan1,*, Elisabet O. Sjöström1, Francis P. Roche1, Chiara Testini1, Naoki Honkura1,
Miguel Sáinz-Jaspeado1, Emma Gordon1, Katie Bentley1,2, Andrew Philippides3, Vladimir Tolmachev1,
Elisabetta Dejana1,4, Radu V. Stan5, Dietmar Vestweber6, Kurt Ballmer-Hofer7, Christer Betsholtz1,8,
Kristian Pietras9, Leif Jansson10 & Lena Claesson-Welsh1

The speciﬁc role of VEGFA-induced permeability and vascular leakage in physiology and
pathology has remained unclear. Here we show that VEGFA-induced vascular leakage
depends on signalling initiated via the VEGFR2 phosphosite Y949, regulating dynamic c-Src
and VE-cadherin phosphorylation. Abolished Y949 signalling in the mouse mutant
Vegfr2Y949F/Y949F leads to VEGFA-resistant endothelial adherens junctions and a block in
molecular extravasation. Vessels in Vegfr2Y949F/Y949F mice remain sensitive to inﬂammatory
cytokines, and vascular morphology, blood pressure and ﬂow parameters are normal.
Tumour-bearing Vegfr2Y949F/Y949F mice display reduced vascular leakage and oedema,
improved response to chemotherapy and, importantly, reduced metastatic spread. The
inﬂammatory inﬁltration in the tumour micro-environment is unaffected. Blocking VEGFAinduced disassembly of endothelial junctions, thereby suppressing tumour oedema and
metastatic spread, may be preferable to full vascular suppression in the treatment of certain
cancer forms.
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ancer is characterized by a dysfunctional and morphologically abnormal vasculature with elevated permeability
and sparse pericyte and basement membrane coating,
resulting in unstable vessels and poor blood ﬂow1. The dismal
condition of the tumour vasculature is attributed to the hypoxic
tumour micro-environment and the accompanying inﬂammation
resulting in the production of a broad range of growth
modulatory factors including vascular endothelial growth
factors (VEGFs), in particular VEGFA (ref. 2). VEGFA causes
increased vascular leakage by disruption of adherens junctions
created through homophilic interactions between vascular
endothelial (VE)-cadherin molecules expressed on adjacent
endothelial cells3. Vessel normalization by titrating an
appropriate level of anti-VEGFA therapy improves the efﬁcacy
of irradiation and chemotherapy4. However, sustained antiVEGFA therapy deteriorates vessel function and may cause
increased hypoxia, increased local tumour cell invasion and
increased metastatic propensity (for a review, see ref. 5). The
role of VEGFA-induced permeability compared with VEGFAregulated migration, survival and proliferation of endothelial cells
is unknown. Moreover, the signal transduction pathways induced
by VEGFA to promote increased vascular permeability have
remained unidentiﬁed.
VEGFA exerts its effects via two endothelial cell receptor
tyrosine kinases denoted VEGFR1 and VEGFR2 (ref. 6). VEGFR1
binds and neutralizes VEGFA, thereby exerting a negative
regulatory effect on endothelial cells, while VEGFR2 is essential
in all known VEGFA biology6. VEGFR2 becomes activated and
phosphorylated on tyrosine residues in response to VEGFA:
Y949, Y1052, Y1057, Y1173 and Y1212 (mouse sequence
numbers)7. The Y949 phosphosite in VEGFR2 (Y951 in human
VEGFR2) presents a speciﬁc binding site for the T cell-speciﬁc
adaptor (TSAd). TSAd is implicated in VEGFA-induced
permeability, by regulating VEGFR2-dependent c-Src signalling
at endothelial cell junctions8. The Y1052/1057 residues, located
on the tyrosine kinase activation loop, are required for full kinase
activity (see ref. 6 and references therein). The phosphorylated
Y1173 binds phospholipase Cg, of importance for endothelial
ERK1/2 pathway activation9. A phenylalanine knock-in mouse
Vegfr2Y1173F/Y1173F is embryonically lethal due to arrested
endothelial cell development10. The Vegfr2Y1212F/Y1212F mouse
lacks a developmental phenotype on a mixed background10.
The aim of the current study was to examine the consequence
of speciﬁc suppression of VEGFA-induced permeability on
cancer progression. VEGFA-induced molecular extravasation

was attenuated in the Vegfr2Y949F/Y949F mouse due to perturbed
signalling through the TSAd/c-Src/VE-cadherin pathway resulting in VEGFA-resistant adherens junctions. The Y949F mutation
however did not perturb other aspects of VEGFA-regulated vessel
biology. The loss of VEGFA-regulated leakage was compatible
with vascular development and a morphologically normal
vasculature including the presence of fenestrated endothelium
in adult organs. Blood ﬂow and blood pressure changes in
response to VEGFA were unaffected by the mutation. In cancer,
the loss of VEGFA-regulated leakage was manifested as reduced
tumour oedema, improved responsiveness to chemotherapy and
suppressed metastatic spread due to an arrest in tumour cell
intravasation.
Results
Vegfr2Y949F/Y949F vessels do not leak in response to VEGFA.
Vegfr2Y949F/Y949F knock-in mice were created using Velocigene
technology11 and used in this study after selection cassette
removal, sequence veriﬁcation and extensive backcrossing onto
the C57Bl/6 background (Supplementary Fig. 1). The mutant
mice were phenotypically normal and expressed similar levels of
VEGFR2 protein in the vasculature as wild-type (WT) mice
(see below). To determine the consequence of Vegfr2Y949F/Y949F
mutation on VEGFA-induced vascular leakage in vivo, we
employed two well-established assays, microsphere extravasation in the tracheal vasculature and Miles extravasation
assay in the dermis. To induce microsphere extravasation,
VEGFA or vehicle was administered by tail vein injection
together with ﬂuorescent 30-nm microspheres. VEGFA-induced
extravasation of microspheres, lodged beneath the basement
membrane in postcapillary venules, was signiﬁcantly reduced at
60 min of circulation in the Vegfr2Y949F/Y949F trachea compared
with WT (Fig. 1a,b). In contrast, tail vein-administered histamine
induced similar levels of microsphere extravasation in WT and
Vegfr2Y949F/Y949F trachea venules (Fig. 1c,d). Moreover, VEGFA
induced a signiﬁcant increase of Evans’ blue leakage in the skin
(Miles assay) in the WT but not in the Vegfr2Y949F/Y949F mouse
(Fig. 1e).
We have previously shown that the phosphorylated Y949 site
in VEGFR2 serves as a binding site for Src homology 2 (SH2)
domain of TSAd8, which in turn binds the SH3 domain of c-Src.
c-Src is known to regulate VE-cadherin and adherens junctions
integrity12. We veriﬁed VEGFA-induced VEGFR2/TSAd complex
formation in the WT and lack of TSAd binding to mutant

Figure 1 | Arrest in VEGFA-induced vascular leakage in Vegfr2Y949F/Y949F mice. (a) Tracheal vessel leakage in WT (left) and Vegfr2Y949F/Y949F (Y949F;
right) mice after tail vein injection of VEGFA or PBS combined with 30 nm ﬂuorescent microspheres (green). Arrows: microsphere leakage from CD31 þ
vessels (red). Scale bar, 50 mm. (b) Microsphere area per CD31-positive area fraction in VEGFA/PBS samples from a. n ¼ 3 mice per genotype. Two-way
ANOVA: P(treatment)o0.0001; P(genotype) ¼ 0.001; P(interaction) ¼ 0.0008. (c) Tracheal vessel leakage in response to tail vein-injected histamine
(as in a), in WT and Vegfr2Y949F/Y949F (Y949F) mice. (d) Microsphere area per CD31-positive area fraction in histamine/PBS samples from c. n ¼ 3–6 mice
per genotype. Two-way ANOVA: P(treatment)o0.0001; P(genotype) ¼ 0.84; P(interaction) ¼ 0.80. (e) Evans’ blue extravasation induced by VEGFA/PBS
in the dermis of WT and Vegfr2Y949F/Y949F (Y949F) mice. Values were normalized to tissue weight. n ¼ 3 mice per genotype. Two-way ANOVA:
P(treatment) ¼ 0.0053; P(genotype) ¼ 0.0206; P(interaction) ¼ 0.0482. (f) VEGFR2/TSAd complex formation in isolated mouse lung endothelial cells
from WT and Vegfr2Y949F/Y949F (Y949F) mice, treated or not with VEGFA. Immunoprecipitation (IP) for VEGFR2 and immunoblotting for TSAd and
VEGFR2. Total lysates were immunoblotted for TSAd and tubulin. Positive control, total lysate. Molecular weight markers to the right. (g) VE-cadherin
immunostaining (yellow–black heatmap) on trachea from WT and Vegfr2Y949F/Y949F (Y949F) mice, tail vein-injected with VEGFA/PBS and microspheres
(pink–red heatmap). Images were rendered using structured illumination microscopy. Note VE-cadherin rearrangement in VEGFA-injected WT trachea.
Scale bar, 10 mm. (h) VE-cadherin fragments per mm vessel length from g. n ¼ 3–6 individual tissues per genotype. Total vessel length assessed: WT/PBS,
236 mm; WT/VEGFA, 308 mm; Y949F/PBS, 150 mm; and Y949F/VEGFA, 145 mm. Two-way ANOVA: P(treatment) ¼ 0.0022; P(genotype) ¼ 0.0065;
P(interaction) ¼ 0.0164. (i) VE-cadherin immunostaining (red) on endothelial cells isolated from WT and Vegfr2Y949F/Y949F (Y949F) mouse lungs and then
treated or not with VEGFA (100 ng ml  1). Hoechst 33342 (blue) staining shows nuclei. Scale bar, 20 mm. (j) VE-cadherin-positive staining per cell; samples
generated as in i. n ¼ 30 cells per condition. Two-way ANOVA: P(treatment) ¼ 0.0189; P(genotype) ¼ 0.099; P(interaction) ¼ 0.0741. Data presented as
mean±s.e.m. Two-way ANOVA with Tukey’s post hoc test, *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001. Experiments were performed at least three
independent times.
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There was no difference in retinal vascular development between
WT and Vegfr2Y949F/Y949F mice as judged by the overall
morphology of the vascular network, the abundance of
endothelial tip cells and ﬁlopodia, and the total vascular area
(Fig. 2a–d). Thus, development of the retinal vasculature does not
depend on VEGFR2-Y949 signalling. However, the morphology
of the VE-cadherin immunostaining differed between the two
genotypes. The VE-cadherin pattern at individual junctions was
evaluated using established image analysis software15, classifying
junctions in a graded scale from ‘active’—that is, being irregular/
serrated with vesicular/diffuse appearance—to ‘inactive’ ones,
presenting a straighter and less vesicular morphology (Fig. 2e, see
Fig. 2f,g for quantiﬁcation and schematic outline). By this
criterion, the WT retinal vasculature displayed a signiﬁcantly
higher prevalence of active adherens junctions compared with the
Vegfr2Y949F/Y949F retinal vasculature (Fig. 2f; active junction
patches was 58.9% (WT) versus 48.1% (Vegfr2Y949F/Y949F);

Table 1 | Haemodynamics in WT and Vegfr2Y949F/Y949F mice.
Strain
pH
Arterial pCO2 (kPa)
Arterial pO2 (kPa)
Base excess (mmol l  1)
Arterial HCO3 (mmol l  1)
Arterial oxygen saturation (%)
S-Na þ (mmol l  1)
S-K þ (mmol l  1)
Haematocrit (%)
Haemoglobin (g l  1)
Blood ﬂow values*
Pancreatic
Whole gland
Caput
Cauda
Duodenal
Colonic
Lung
Kidney
CNS
Fat
CNS, central nervous system.
Values are means±s.e.m.
*ml min  1  g organ weight.

WT
(n ¼ 9)
7.29±0.01
5.8±0.3
13.1±0.9
 5.8±0.6
20.7±0.7
95.6±1.0
144.8±0.6
5.1±0.2
32.3±1.1
110±4

Y949F
(n ¼ 8)
7.32±0.02
5.5±0.3
14.7±0.6
 4.6±1.0
21.3±1.1
97.5±0.4
143.2±0.5
5.2±0.2
33.0±1.6
112±5

1.76±0.36
1.42±0.22
2.10±0.48
1.47±0.20
1.52±0.32
1.38±0.24
4.57±1.21
3.60±0.70
1.51±0.24
1.48±0.47
0.15±0.07
0.21±0.09
7.15±1.65
5.69±1.28
1.07±0.18
1.64±0.48
0.013±0.004 0.008±0.003

P
value
0.288
0.596
0.167
0.341
0.661
0.185
0.09
0.757
0.73
0.732

0.458
0.532
0.735
0.514
0.361
0.665
0.503
0.47
0.768

P ¼ 0.0367, calculated using median% in one-tailed Wilcoxon
rank sum test.
Still, the enhanced barrier morphology in the VEGFR2-Y949F
mutant did not interfere with overall vascular morphology or
physiology. The adult vascular ultramorphology of the kidney
glomeruli and peritubular capillaries (Fig. 2h) and the pancreas
(Supplementary Fig. 2f) was normal in the Vegfr2Y949F/Y949F
mouse. Moreover, expression of plasmalemma vesicle-associated
protein-1 (PV1), which is required for the formation of
diaphragms covering endothelial fenestrae in vessels of endocrine
organs16 was not affected by the VEGFR2-Y949F mutation
(Fig. 2i).
To exclude the possibility that vascular leakage arrest in the
Vegfr2Y949F/Y949F mouse was inﬂuenced by blood pressure/ﬂow
parameters, a series of in vivo tests were performed. The resting
blood pressure in the descending aorta was monitored continuously while infusing VEGFA or phosphate-buffered saline
(PBS) by tail vein injection. VEGFA, but not PBS, caused a
signiﬁcant drop in blood pressure as an indication of vessel
dilation, in both WT and Vegfr2Y949F/Y949F mice (Fig. 2j).
Moreover, blood parameters including arterial gases, oxygen
saturation, serum Na þ /K þ levels, as well as the haematocrit/
haemoglobin levels were similar in the WT and Y949F conditions
(Table 1). Tail vein injection of lectin showed that the WT and
Vegfr2Y949F/Y949F tracheal vessels were perfused to the same
extent (Supplementary Fig. 2g), supporting the notion that the
leakage arrest in the mutant mouse vasculature was not due to
altered circulation. Pericyte morphology (Fig. 2k,l) and basement
membrane coating (Fig. 2m,n) were similar between the
genotypes. Moreover, RNAseq analyses did not reveal major
differences in expression levels of key endothelial transcripts
between the WT and the Vegfr2Y949F/Y949F condition (Fig. 2o).
Reduced Vegfr2Y949F/Y949F glioblastoma vessel leakage. The
integrity of the central nervous system vasculature is tightly
controlled by the blood–brain barrier, in which endothelial
junctions are particularly tight17. We asked whether VEGFAregulated vascular leakage has an impact on the growth and
vascular permeability of brain tumours. The GL261 glioma model
has many features reminiscent of human glioma, including
abnormal vasculature, high VEGFA production and oedema18.
GL261 glioma cells were injected in the right medial striatum of
WT and Vegfr2Y949F/Y949F mice. There was no effect on tumour
growth at any examined time point after cell inoculation (day 7
(D7), D14, D18 and D21; Fig. 3a shows tumour volume at D18).
There was also no difference in the extent of perfused vessel

Figure 2 | Vegfr2Y949F/Y949F vessel parameters. (a) Isolectin-B4 (IB4, red) and ERG (green) immunostaining on WT and Vegfr2Y949F/Y949F (Y949F) P6
retinal vasculature. Scale bar, 100 mm. (b) Tip cells numbers. n ¼ 3–4 retinas per genotype. (c) IB4-positive vessel area normalized to WT. n ¼ 3–4 retinas per
genotype. (d) Radial vessel outgrowth normalized to WT. n ¼ 4–5 retinas per genotype. (e) Heatmap of VE-cadherin morphology in WT and Vegfr2Y949F/Y949F
(Y949F) P6 retinas. Scale bar, 50 mm. (f) Retinal images in e processed for VE-cadherin morphology, lying within the vascular mask, into ‘patches’ of
100  100 pixels (  63, n ¼ 6 per group). The VE-cadherin morphology in each patch was hand-classiﬁed according to the classiﬁcation key in g. (g)
Adherens junctions classiﬁcation from ‘active’ (red; irregular/serrated morphology with diffuse/vesicular regions) to ‘inactive’ (blue; straighter morphology
with less vesicular staining). (h) Transmission electron microscopy analysis of kidney glomerulus and peritubular capillary (cap) show normal appearance of
junctions (red arrows) and fenestrae (insets) in the two genotypes. (i) PV1 protein immunoblot in lung lysates after injection of PBS (P) or VEGFA (V) and
circulation for 1–10 min (P1; injection of PBS and 1 min circulation and so on). GAPDH; equal loading. Molecular weight markers to the right. (j). Blood pressure
10 min after saline or VEGFA infusion, monitored in the ascending aorta. Values (positive or negative) show diastolic blood pressure (BP) normalized
to BP before VEGFA/PBS injection (70 mm Hg; NS between genotypes). n ¼ 6–8 mice per genotype. Student’s t-test, *Po0.05. Two-way ANOVA:
P(treatment) ¼ 0.0001; P(genotype) ¼ 0.738; P(interaction) ¼ 0.5321. (k) CD31-positive (red) tracheal endothelium and desmin-positive (green) pericytes.
Scale bar; 50 mm. (l) Pericyte area per total area from k. n ¼ 4 mice per genotype. (m) CD31-positive (red) tracheal endothelium and collagen IV-positive
(green) basement membrane. Scale bar; 50 mm. (n) Collagen IV area per total area in m. n ¼ 3 mice per genotype. (o) RNAseq analysis of total lung polyA þ
RNA. Data for selected endothelial genes as log10-scaled fold-change based on the frequency of normalized expression. For Vegfr2 (KDR) the Y949F mutant
showed a  0.24 (DESeq2log2) fold decrease compared with WT. Data presented as mean±s.e.m. Student’s t-test (b–d) and Wilcoxon rank test (f); NS, not
signiﬁcant. Experiments were performed three independent times or performed once with at least three independent data sets (j,o).
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RIP1-TAg2:Vegfr2Y949F/Y949F leakage and metastatic spread.
The consequence of the stabilized endothelial junctions in
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(Fig. 4b). Conversely, the RIP1-TAg2:Vegfr2Y949F/Y949F presented
with fewer large (45 mm) neoplastic islet tumours (Fig. 4c).
Tumour cells were found in close proximity to the vasculature
in the tumour periphery suggesting metastatic spread of the
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density (Fig. 3b). However, leakage of tail vein-injected
cadaverine-Alexa-555, a small tracer that normally does
not cross the blood–brain barrier19, was reduced in the
Vegfr2Y949F/Y949F gliomas compared with WT at D18, both
intratumourally and in the tumour periphery (0–500 mm
peritumourally; Fig. 3c). The glioma vasculature in the WT was
more disorganized than in the Vegfr2Y949F/Y949F (Fig. 3d).
Hotspots of ﬂuorescent lectin leaking from perfused vessels
(Fig. 3d, boxed area) correlated with high tumour uptake of
Cadaverine-555 (Fig. 3e) in the WT compared with the mutant.
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Figure 3 | Reduced glioblastoma permeability in Vegfr2Y949F/Y949F mice. (a) GL261 glioma volumes at D18, estimated by measuring all tumourcontaining sections in series throughout the brain of WT and Vegfr2Y949F/Y949F (Y949F) mice. n ¼ 13–14 mice per genotype. (b) Lectin-positive, perfused
vessel density (area fraction per tumour area) at D18. n ¼ 12–14 mice per genotype. (c) Cadaverine-555 ﬂuorescence intensity units estimated within the
tumour (intratumoural) and at a 0–500-mm rim around the tumour border (peritumoural), Y949F normalized to WT. n ¼ 8–11 mice per genotype.
(d) GL261 lectin-perfused vessels (lectin in green). Boxed area, typical point of leakage/disrupted barrier in the WT. (e) Cadaverine-555 (red)
extravasation in WT and Y949F GL261 gliomas. Scale bar, 100 mm (d) and 50 mm (e). Data are presented as mean±s.e.m. Student’s t-test, *Po0.05,
**Po0.01. Experiments were performed three independent times. NS, not signiﬁcant.

Figure 4 | Reduced RIP1-TAg2 vascular leakage and metastatic spread in Vegfr2Y949F/Y949F. (a) RIP1-TAg2 WT and Vegfr2Y949F/Y949F insulinoma tumour
volumes at week 14. n ¼ 19–21 mice per genotype. (b) Angiogenic islet numbers at week 14. n ¼ 14–16 mice per genotype. (c) Tumour size distribution (1–5
and 45 mm diameter), week 14. n ¼ 17–19 mice per genotype. (d) Tumour cells (SV40 T antigen þ ; green) and vessels (CD31 þ ; red) in RIP1-TAg2
insulinomas (left), Arrows; individual tumour cells associated with vessels. Scale bar, 100 mm. SV40 T antigen þ (green; upper) and haematoxylin-eosin (HE;
lower) metastatic liver lesion (right). Scale bars, 50 mm. Number of liver metastases; mean per section, 30 sections per liver. n ¼ 11–17 mice per genotype.
(e) Leakage of 30-nm microspheres (green; arrows) from VE-cadherin þ tumour vessels (red). Scale bar, 50 mm. (f) Microspheres area per VE-cadherin area
from e. n ¼ 10–11 tumours per genotype. (g,h) VE-cadherin þ (red) and podocalyxin þ (green) RIP1-TAg2 tumour vasculature. Lower panels, magniﬁcation of
boxed areas in upper panels. Arrows indicate typical disorganized podocalyxin in WT tumour vasculature. Scale bars, 50 mm (g), 5 mm (h). (i) VE-cadherin
area, % of total area from g. n ¼ 15–17 tumours per genotype. (j) Podocalyxin area, % of total area from g. n ¼ 15–17 tumours per genotype. Data shown as
mean±s.e.m. Student’s t-test, *Po0.05, **Po0.01, NS, not signiﬁcant. Data are pooled from three independent studies.
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insulinoma (Fig. 4d). Examination of livers showed that the
number of SV40 T-positive liver metastases in the RIP1-TAg2:WT
was signiﬁcantly higher than in RIP1-TAg2:Vegfr2Y949F/Y949F
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mice at week 14 (Fig. 4d). We hypothesized that reduced
metastatic spread in RIP1-TAg2:Vegfr2Y949F/Y949F mice could
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Figure 5 | Reduced B16F10 vascular leakage and metastatic spread in Vegfr2Y949F/Y949F. (a) Subcutaneous B16F10 tumour volumes for WT (blue) and
Vegfr2Y949F/Y949F (Y949F; magenta) mice at different days after inoculation. n ¼ 14–15 mice per genotype. Repeated measures ANOVA: P(time)o0.0001;
P(genotype) ¼ NS. (b) CD31 þ area per ﬁeld in B16F10 tumours from WT and Y949F mice. n ¼ 21 mice per genotype at D12 and 11–16 mice per genotype at
D18. (c) Area of tomato lectin-perfused vessels normalized to CD31 þ area. n ¼ 21 mice per genotype, D12; and 11–16 mice per genotype at D18. *Po0.05.
(d) Tumour vasculature (upper panels; CD31 þ vessels; white) and perivascular ﬁbrinogen deposition (lower panels, heatmap from red, high, to blue, low) in
B16F10 tumours from WT and Vegfr2Y949F/Y949F mice at D12. Scale bars, 50 mm. (e) Fibrinogen þ area normalized to CD31 þ area. n ¼ 22–27 mice per
genotype at D12 and 13–14 mice per genotype at D18. Student’s t-test, P ¼ 0.0310. (f) Oedema in B16F10 tumours estimated by weighing tumours before
and after drying. Data show (wet weight  dry weight)/wet weight in % at D12 and D18. n ¼ 16-18 mice per genotype at D12 and 19–24 mice per genotype
at D18. Student’s t-test, P ¼ 0.0385. (g) Tumour volumes at D12 of TMZ or vehicle (dimethylsulfoxide)-treated mice with B16F10 tumours, receiving
treatment between D4 and D8 after inoculation. n ¼ 12–15 mice per group. Kruskal–Wallis test, P ¼ 0.0289. (h) B16F10 tumour volumes in mouse ear.
n ¼ 12–13 mice per genotype. Repeated measures ANOVA: P(time)o0.0001; P(genotype) ¼ NS. (i) Spontaneous B16F10 lung metastasis spreading to the
lungs from primary B16F10 tumours in the ear. dsred-B16F10 metastases in four longitudinal sections of each left main lung lobe were counted. n ¼ 12 mice
per genotype. Mann–Whitney U, P ¼ 0.0028. Data shown as mean±s.e.m. Dashed lines in b,c,e and f indicate that data sets from D12 and D18 were not
compared statistically. *Po0.05, **Po0.01, NS, not signiﬁcant. Experiments were performed three independent times (a–e,h–j) or two times (f,g),
and data were pooled.
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microspheres leaked from tumour vessels to a higher extent in
RIP1-TAg2:WT than in RIP1-TAg2:Vegfr2Y949F/Y949F tumours
(Fig. 4e,f). In the RIP1-TAg2:Vegfr2Y949F/Y949F tumour
vasculature, VE-cadherin was preferentially localized at
endothelial junctions and the VE-cadherin area was lower than
in the WT (Fig. 4g–i). Moreover, staining for the sialomucin
podocalyxin decorated the luminal endothelial surface in the
RIP1-TAg2:Vegfr2Y949F/Y949F tumour vasculature while RIP1TAg2:WT tumours showed a chaotic podocalyxin staining
pattern suggestive of altered apical–basal (luminal–abluminal)
endothelial polarity (Fig. 4g,h,j) and therefore, disturbed vessel
organization. The extent of vessel perfusion, pericyte coating and
inﬂammatory cell inﬁltration (that is, CD45, F4/80 and
macrophage mannose receptor (MMR)-positive cells did,
however, not differ between RIP1-TAg2:WT and RIP1TAg2:Vegfr2Y949F/Y949F tumours at week 14 (Supplementary
Fig. 3a–e).
B16F10 vessel leakage and metastatic spread. To further test the
effect of the VEGFR2-Y949F mutation on vascular integrity in
cancer, we chose to study subcutaneous B16F10 melanoma22.
B16F10 tumour growth in the back skin was monitored
continuously showing similar growth curves for the two
genotypes (Fig. 5a). To monitor dynamic changes in tumour and
vascular parameters, tumours were collected at two different time
points after inoculation, at D12 (average tumour volume 200 mm3)
and at D18 (average tumour volume 1.5 cm3) from WT and
Vegfr2Y949F/Y949F mice. Vascular area (Fig. 5b) and pericyte density
(Supplementary Fig. 3f) were similar in WT and Vegfr2Y949F/Y949F
B16F10 tumours at D12 and D18. Vessel functionality as assessed
by lectin perfusion was more efﬁcient in the Vegfr2Y949F/Y949F
tumour vasculature at D12 (Fig. 5c). At D18, vessel perfusion had
improved in the WT and was similar to that of Vegfr2Y949F/Y949F
tumours. In spite of the improved perfusion, necrosis in the tumour
was similar in the two genotypes (Supplementary Fig. 3g).
Importantly, there were no differences in inﬁltration of F4/80 þ ,
CD45 þ and MMR-positive inﬂammatory leukocytes in the
tumours at D12 (Supplementary Fig. 3h–j).
Vessel leakage in B16F10 tumours, determined by estimating
the deposition of perivascular ﬁbrinogen (Fig. 5d; quantiﬁed in e),
was signiﬁcantly lower in Vegfr2Y949F/Y949F tumours compared
with WT tumours at D12. At D18, ﬁbrinogen deposition was
reduced in the WT tumours and similar between the two
genotypes. Vascular leakage in tumours leads to oedema, which
was estimated by weighing tumours before and after drying. The
water content of Vegfr2Y949F/Y949F tumours was signiﬁcantly
lower than in WT tumours at D12 (Fig. 5f) but not at D18.
Altogether, these data indicate that the block in VEGFR2 pY949
signalling constrained vascular leakage and oedema in the tumour
up to a critical point in tumour growth, occurring around D12.
Thereafter, leakage and oedema were reduced irrespective of
genotype, possibly due to an overall dysfunctional tumour
circulation.
To test the effect of chemotherapy on tumours exhibiting
different extents of vessel leakage and oedema, B16F10 tumourbearing mice were treated with a subtherapeutic dose of
temozolomide (TMZ) or vehicle in one cycle for 5 consecutive
days. Tumour growth in WT mice was resistant to the
TMZ treatment at the given dose. In contrast, TMZ-treated
Vegfr2Y949F/Y949F mice had smaller tumours than WT at D12
(Fig. 5g) but not at D18 (Supplementary Fig. 4a). Thus,
the VEGFA-resistant vessel barrier phenotype in the
Vegfr2Y949F/Y949F tumours correlated with an enhanced drug
effect at D12, probably due to the lower oedema, and hence a
lower interstitial tumour pressure, at this stage.

To study B16F10 metastasis, dsRed-B16F10 cells were
inoculated intradermally in the ear. Tumour growth rate is
constrained in the ear dermis, which we found correlated with an
increased propensity to metastasize compared with when
tumours grow unconstrained in the back skin. The primary
tumour growth rate was similar between Vegfr2Y949F/Y949F
and WT mice (Fig. 5h). Metastatic spread from the primary
dsRed-B16F10 tumour to the lungs was however signiﬁcantly
reduced in the Vegfr2Y949F/Y949F mice (Fig. 5i). There was no
correlation between the end point weight of the primary tumour
and the number of metastatic foci (Supplementary Fig. 4b). We
further tested the capacity of tail vein-injected dsRed-B16F10
tumour cells to colonize lungs and found no difference in lodging
frequency between the genotypes (Supplementary Fig. 4c).
In vivo signalling in the Vegfr2Y949F/Y949F endothelium. To
decipher signalling regulating VEGFA-induced vascular leakage
in vivo, mice were subjected to tail vein injection of VEGFA or
vehicle, and lungs were collected after different time periods of
circulation (1–60 min). Lungs were chosen since they consist at
least 50% of endothelial cells. Moreover, we used the two-tracer
technique23 to show that WT lung endothelial cells respond to
VEGFA with increased transvascular leakage of iodinated
albumin in vivo. The leakage rate in WT mice increased
2.5-fold after VEGFA injection in the tail vein, compared with
vehicle (ﬂow rate in response to VEGFA, 0.859±0.114 versus
vehicle, 0.334±0.126 ml min  1 g  1; s.e.m., P ¼ 0.0278, n ¼ 3–4
mice per condition).
VEGFA induced a very rapid and strong phosphorylation of
VEGFR2 at Y1173 in WT and to a lower relative level in the
Vegfr2Y949F/Y949F lung endothelium (Fig. 6a). Phosphorylation at
Y949 was also high at 1 min after VEGFA injection in the WT,
whereas it was absent in the Vegfr2Y949F/Y949F vasculature
(Supplementary Fig. 5a). The lower pY1173 accumulation in
the Vegfr2Y949F/Y949F could be due to the more extensive
complex formation with the vascular endothelial protein tyrosine
phosphatase (VEPTP). As shown in Supplementary Fig. 5b, there
was a signiﬁcantly higher extent of VEPTP/VEGFR2 complex
formation in the Vegfr2Y949F/Y949F immunoprecipitates compared
with WT VEGFR2 (two-way analysis of variance (ANOVA),
genotype effect: P ¼ 0.0037). VEPTP has been shown to restrict
VEGFR2 tyrosine phosphorylation24.
Several signalling pathways regulate vascular permeability and
leakage, including VEGFA-induced c-Src signalling8,25 and
histamine-induced phosphoinositide 3 kinase/Akt signalling26,
which both induce phosphorylation of VE-cadherin and
VE-cadherin internalization. We examined induction of pY658
VE-cadherin by immunoblotting of VEGFR2 immunoprecipitates
from mouse lungs. We choose to study VE-cadherin in complex
with VEGFR2 to monitor direct communication between the two.
In the WT, the levels of pY658 VE-cadherin were already high in
the PBS-injected mice in agreement with previous reports27, and
remained high initially after injection of VEGFA, followed by a
gradual decrease possibly due to the action of phosphatases, or to
internalization and degradation of VE-cadherin (Fig. 6a). In the
Vegfr2Y949F/Y949F-derived samples, the pVE-cadherin level was
low in the PBS condition and there was no induction with
VEGFA injection (Fig. 6a).
Tyrosine phosphorylation of c-Src was difﬁcult to detect in the
VEGFR2 immunoprecipitates from lung lysate and was therefore
examined in total lung lysates (Fig. 6b). In the WT samples, we
detected an increased accumulation of pY418 c-Src only at the
late time point, in agreement with previous data where c-Src
activation was detected in lung lysates 20 min after tail vein
injection of VEGFA8. In the Vegfr2Y949F/Y949F mouse lungs,
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Figure 6 | VEGFA-induced signalling in
(a) VEGFR2 immunoprecipitation (IP) and immunoblotting (IB) for pY1173VEGFR2, VEGFR2,
pY658VE-cadherin and VE-cadherin from lung lysates after tail vein injection of PBS (P) or VEGFA (V) in WT and Vegfr2Y949F/Y949F (Y949F) mice, followed
by circulation for different time periods (P1, P2, P5: PBS injection and circulation for 1, 2 or 5 min; V1, V2, V5, V10, V15, V60: VEGFA injection and circulation
for 1, 2, 5, 10, 15 or 60 min). Quantiﬁcation shown to the right; n ¼ 4. Groups of early (V1–V2), intermediate (V5, V10, V15) and late (V60) time points were
quantiﬁed. Phosphoform/total protein band densities were normalized to the mean of all PBS samples. Two-way ANOVA, upper (p1173VEGFR2):
P(genotype) ¼ 0.032, P(time) ¼ 0.0009; lower (VE-cadherin): P(genotype) o0.0001, P(time) ¼ 0.0049. (b) VEGFA-induced accumulation of pY418 Src
(upper) and pT308 Akt (lower) in total lung lysates (TLL) from Vegfr2Y949F/Y949F (Y949F) mice. Quantiﬁcation as in a, relative to the unphosphorylated
c-Src and Akt pools and normalized to mean PBS values. Two-way ANOVA, upper (Src): P(genotype) ¼ 0.0137, P(time) ¼ NS; lower (Akt):
P(genotype) ¼ NS, P(time) ¼ 0.0013. (c) Quantiﬁcation (top) of IB (bottom) for pY1173VEGFR2 and VEGFR2 in VEGFR2 immunoprecipitates (IP) from
B16F10 tumours at D12 and D18 after inoculation of WT and Vegfr2Y949F/Y949F (Y949F) mice. n ¼ 19/WT D12, 14/WT D18, 15/Y949F D12 and 14/Y949F
D18. (d) Quantiﬁcation (top) of IB (bottom) for pY418Src and c-Src in VEGFR2 immunoprecipitates (IP) from tumour lysates as in c. n ¼ 19/WT D12, 13/
WT D18, 14/Y949F D12 and 14/Y949F D18. (e) Quantiﬁcation (top) of IB (bottom) for VEPTP and VEGFR2 on VEGFR2 immunoprecipitates (IP) from
tumour lysates as in c. n ¼ 19/WT D12, 14/WT D18, 15/Y949F D12 and 14/Y949F D18 tumours. Data shown as mean±s.e.m. Dashed lines in c–e indicate
that data sets from D12 and D18 were not compared statistically. In a,b two-way ANOVA, with Sidak’s post hoc test; in c–e Student’s t-test. *Po0.05,
**Po0.01, ***Po0.0001, ****Po0.00001. Experiments were performed four independent times.
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Figure 7 | Schematic outline of Y949 signalling in VEGFA-regulated vascular permeability. WT and Vegfr2Y949F/Y949F (Y949F) endothelial junctions are
shown (upper). In the WT, the junction is active, that is, VE-cadherin is not engaged in homophilic interaction, and VEGFA signalling results in c-Src
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oedema are blocked and metastatic spread is suppressed, while inﬂammatory cell extravasation is unaffected.

tyrosine phosphorylation of c-Src Y418 increased with VEGFA
during the early phase but did not accumulate in the later phase
of signalling (Fig. 6b, upper). Thus, the proﬁles of VEGFAinduced, endothelial c-Src phosphorylation differed between the
WT and Vegfr2Y949F/Y949F mice. On the other hand, pT308AKT,
examined in total lung lysates, accumulated with relatively slow
and similar kinetics in the WT and Vegfr2Y949F/Y949F lungs in
response to VEGFA injection (Fig. 6b, lower). These data indicate
that the VEGFR2-Y949F mutation interfered with c-Src
activation and pathways downstream of c-Src, including
VE-cadherin phosphorylation at Y658.
VEGFA signalling in B16F10 tumours was examined to
understand how leakage was regulated in a tumour context.
Immunoblotting of lysates from individual tumours showed that
the pY1173/VEGFR2 ratio was signiﬁcantly higher at D12 in
tumours from WT mice compared with Vegfr2Y949F/Y949F
mice (Fig. 6c; lower part shows representative immunoblot),
correlating with the VEGFA signalling data from lung lysates
(Fig. 6a). At D18, the pVEGFR2/VEGFR2 ratios were similar
between the genotypes. The results on the pVEGFR2/VEGFR2
levels are likely to reﬂect the status in the tumour vasculature, as
B16F10 cells do not express VEGFR2 (ref. 28). Immunoblotting
for pY418Src in the VEGFR2 immunoprecipitates from tumour
lysates showed a signiﬁcantly higher pSrc/Src ratio in the D12
tumours from WT mice compared with Vegfr2Y949F/Y949F mice
(Fig. 6d; lower part shows representative blot). At D18, there was
no difference between the genotypes in the extent of pSrc
accumulation.

The restriction in VEGFR2 signalling in tumours from the
Vegfr2Y949F/Y949F mice at D12 may involve dephosphorylation of
VEGFR2 by VEPTP, as we found increased levels of VEGFR2/
VEPTP complexes in the Y949F condition (Fig. 6e; lower part
shows representative blot). VEPTP expression levels in D12
tumours did not differ between the genotypes (Supplementary
Fig. 5c). At D18, VEGFR2/VEPTP complex formation was similar
between WT and Vegfr2Y949F/Y949F-derived tumours (Fig. 6e).
For uncropped versions of all blots presented in this study, see
Supplementary Figs 6–13.
We conclude that VEGFA-induced leakage (see Fig. 7 for a
schematic outline of VEGFA signalling regulating vascular
permeability/leakage) can be restricted during a window of time
of B16F10 tumour growth, by suppressing the pY949 pathway.
Moreover, the data indicate that VEGFA signalling is dynamically
regulated by VEPTP in solid tumours.
Discussion
Here we show that a speciﬁc arrest in VEGFA-induced vascular
permeability leading to attenuation of molecular extravasation
in organs such as the trachea and skin is compatible with
normal vascular development, morphology and function. The
Vegfr2Y949F/Y949F mouse displayed reduced vascular leakage in
several orthotopic tumour models and a signiﬁcant reduction in
metastatic spread of insulinoma and melanoma (see Fig. 7 for a
schematic summary of the results). The enhanced vascular barrier
in the Vegfr2Y949F/Y949F mouse led to reduced tumour oedema,
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allowing for increased chemotherapeutic efﬁcacy. While our data
strongly indicate that signalling via pY949-VEGFR2 regulates
c-Src activation and VE-cadherin phosphorylation and
therefore adherens junction integrity, we do not rule out the
involvement of transendothelial pores/vesiculovacuolar organelles
in VEGFA-induced vascular permeability29.
Induced vascular permeability, also denoted vascular
hyperpermeability or vascular leakage, may be acute or chronic30.
The best studied factors regulating vascular leakage include
VEGFA and inﬂammatory cytokines such as histamine and
bradykinin31. An implication from the current study is that
VEGFA dominates over inﬂammatory cytokines in regulating
molecular extravasation, in the models studied here. VEGFA was
originally identiﬁed as a vascular permeability factor30, but the
physiological role of vascular permeability regulated by VEGFA/
VPF has remained unclear. Dvorak and colleagues implicated
vascular permeability in the formation of a provisional matrix for
the growth of new vessels32. Our data do not support an essential
role for the VEGFA-driven pathway regulated by VEGFR2 pY949
signalling, in angiogenesis.
Cheresh and coworkers have shown the critical role for
c-Src-pathways in regulation of VEGFA-induced vascular
permeability25. Our work extends these data by implicating
pY949-VEGFR2/TSAd in regulation of c-Src pY418, VE-cadherin
pY658 and the stability of adherens junctions. VE-cadherin is
constitutively tyrosine phosphorylated in postcapillary venules
compared with arteries/arterioles and regulated through ﬂowinduced activation of c-Src, as judged from immunoﬂuorescent
staining of different capillary beds27. In this study, we noted a
marked reduction in VE-cadherin Y658 phosphorylation in the
Vegfr2Y949F/Y949F lung lysates compared with WT, in agreement
with the altered c-Src phosphorylation proﬁle (Fig. 6a,b) and with
the persistence of adherens junctions in response to VEGFA,
in vivo and in vitro (Fig. 1g–j). However, the complex biology of
c-Src precludes a direct cause–effect relationship between c-Src
pY418 phosphorylation and VE-cadherin/adherens junction
stability. We have previously shown that pY418 Src
accumulates with relatively slow kinetics in vivo and that it
translocates to junctions in complex with the adaptor molecule
TSAd8. It is possible that the dynamics of c-Src activation differs
between different subcellular compartments such as junctions
and focal adhesions. Thus, at focal adhesions, c-Src activity is
induced as a consequence of cell adhesion-dependent focal
adhesion kinase activation, which also affects vascular
permeability most likely by orchestrating cell shape33. In
agreement with the data presented here, focal adhesion kinase
(Ptk2) gene knockout decreases tumour spread34. Owing to
technical constraints imposed by the quality of commercial c-Src
antibodies, we have not been able to distinguish different
subcellular pY418 Src pools in vivo. However, accumulation of
pY418 Src in relation to the total c-Src pool was decreased both in
Vegfr2Y949F/Y949F lung endothelial cells and in B16F10 tumours
growing in mutant mice.
VEGFA-induced accumulation of pT308 Akt was similar in the
WT and mutant Y949F VEGFR2 conditions. Akt plays an
important role in vascular permeability induced by inﬂammatory
cytokines26. Akt is critical for the activation of endothelial NO
synthase (eNOS) in vivo, by phosphorylation on Ser1176 (ref. 35),
resulting in increased NO production. NO, a potent regulator of
the vascular tone, mediates vasodilation by stimulating soluble
guanylyl cyclase and increasing cyclic GMP in smooth muscle
cells36. In this study, we recorded transiently reduced blood
pressure indicative of vasodilation in response to VEGFA in the
descending aorta (Fig. 2j) in both WT and Vegfr2Y949F/Y949F mice.
This result together with the full activation of Akt, judged from
the pattern of pT308 Akt accumulation in the mutant, indicate
12

that the NO pathway is intact in the Vegfr2Y949F/Y949F mouse.
eNOS has previously been implicated in tumour vascular
permeability, and inhibition of eNOS activity by a small
caveolin-derived peptide (cavtratin) leads to suppressed tumour
vascular permeability and reduced primary tumour growth
without affecting blood ﬂow and angiogenesis37. In contrast,
while metastatic spread was suppressed in the Vegfr2Y949F/Y949F
mouse, primary tumour growth was only modestly affected.
We noted reduced phosphorylation of VEGFR2 at phosphosite
Y1173 in the Vegfr2Y949F/Y949F lungs and in D12 B16F10
melanoma. Mutation of the human tyrosine residue, Y951
(corresponding to mouse Y949), in a puriﬁed recombinant
intracellular VEGFR2 domain interferes with protein folding38.
Whether protein folding is affected also in the full-length
VEGFR2 remains to be shown. We noted that the level of
phosphorylation of the full-length mouse VEGFR2-Y949F
mutant relative to WT VEGFR2 varied during tumour
progression. Thus, in B16F10 tumours, the relative level of
pY1173 in WT VEGFR2 was higher than for VEGFR2-Y949F at
an early stage, whereas the levels were similar at later stages of
tumour growth. We propose that the reduced VEGFR2
phosphorylation in the Vegfr2Y949F/Y949F lungs in D12 B16F10
tumours at least in part was a consequence of sustained
VEGFR2/VEPTP complex formation. VEPTP is a receptor-type
phosphotyrosine phosphatase speciﬁcally expressed in endothelial
cells and known to have VE-cadherin and Tie2 as direct
substrates39. VEGFR2 is an indirect substrate for VEPTP,
resulting in dephosphorylation of VEGFR2 in complex with
Tie2 (ref. 24). Here we conﬁrm and extend the data on the
important role of VEPTP as an in vivo regulator of VEGFR2
activity. VEGFR2/VEPTP complex formation correlated with
VEGFR2 pY1173 levels and the extent of oedema. Thus, B16F10
melanomas in WT mice showed low VEGFR2/VEPTP complex
formation, high p1173 VEGFR2 levels and prominent oedema.
In contrast, melanomas in the Vegfr2Y949F/Y949F mice displayed
high VEGFR2/VEPTP complex formation, low p1173 pVEGFR2
levels and reduced oedema. With time, VEPTP/VEGFR2
complex formation decreased in tumours from both WT and
Vegfr2Y949F/Y949F mice. Still, the VEGFR2 and c-Src activities
were suppressed in the late stage of tumour growth in WT mice,
showing a restriction in VEGFA signalling independent of
VEPTP. The gradual progression towards lower VEGFR2 phosphotyrosine levels over time is in agreement with models for
resistance towards anti-VEGFA neutralizing therapy in cancer40.
The extent of tumour oedema correlates to the blood supply,
the volume of blood entering the tumour and the lymphatic
drainage41. Tumour blood supply decreases as the tumour mass
increases42, most likely due to a progressive deterioration of the
tumour vasculature with eventually fewer functional vessels.
Tumours in Vegfr2Y949F/Y949F mice were less oedematous, which
we attribute to the higher vessel integrity in the mutant. Excess
and persistent extravasation increases the interstitial pressure and
impairs delivery of therapeutics to the tumour tissue4. In
agreement, the B16F10 tumour-bearing Vegfr2Y949F/Y949F mice
were more responsive to treatment with chemotherapy. Complete
sealing of junctions to VEGFA, as well as to inﬂammatory
cytokines, as a result of expression of a VE-cadherin/a-catenin
fusion protein, leads to a partial reduction in inﬂammatory
cell extravasation43. In contrast, restricting VEGFA-induced
permeability alone as in the Vegfr2Y949F/Y949F genotype, failed
to suppress inﬂammatory cell inﬁltration in RIP1-TAg2
insulinomas (Supplementary Fig. 3c–e) and B16F10 melanomas
(Supplementary Fig. 3h–j). While we do not exclude that acute
inﬂammation or other aspects of inﬂammation not studied here
are affected by the VEGFR2 mutation, our data suggest that there
is no direct relationship between the capacity to spread metastasis
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and primary tumour inﬂammation. Moreover, lodging of
circulating tumour cells was unaffected by the mutation
(Supplementary Fig. 4b) suggesting that the stable Vegfr2Y949F/
Y949F junctions may restrict the ability of tumour cells to enter
but not exit the circulation. The caveats of the experimental
metastasis model44 (that is, injection of tumour cells in the tail
vein followed by lodging of tumour cells in the lung) compared
with spontaneous metastasis, limits conclusions however.
Possibly, factor(s) other than VEGFA may contribute
to extravasation of B16F10 cells in the lung; indeed, the
Vegfr2Y949F/Y949F endothelium retains sensitivity to other
permeability-inducing factors than VEGFA such as histamine.
It is pertinent to ask whether the reduced metastatic spread in the
Vegfr2Y949F/Y949F tumours can be attributed directly to the
VEGFA-resistant Y949F junctions, that is, do tumour cells
intravasate into the circulation via junctions? Alternatively, were
other parameters, established as a consequence of the nonleaky
junctions and the reduced oedema, more important? As we
did not record signiﬁcant changes compatible with vascular
normalization4, that is, in vascular density, pericyte coating,
necrosis or inﬂammation in the B16F10 melanomas from WT
and mutant mice, we propose that the Vegfr2Y949F/Y949F
phenotype primarily depends on the VEGFA-resistant junctions.
In conclusion, our data suggest that speciﬁcally suppressing
VEGFA-induced vascular permeability without attenuation of
vital aspects of VEGFA biology, for example, endothelial survival
and neoangiogenesis, may offer an attractive strategy in future
drug development to reduce oedema, to improve therapeutic
efﬁcacy and to suppress metastatic spread in cancer.
Methods

Vegfr2Y949F/Y949F mouse model. A mouse model with knock-in of phenylalanine
(F) to replace the tyrosine (Y) at position 949 (Y951 in the human) of VEGFR2
(designated Vegfr2Y949F/Y949F) in a mixed 129S6/C57BL/6 was created using
VelociGene technology (Regeneron Pharmaceuticals, New York, USA)11. The
Vegfr2Y949F/Y949F mouse was backcrossed onto the C57BL/6 background for
more than 10 generations and maintained through crossing of Vegfr2Y949F/Y949F
heterozygotes. All data shown are based on comparison of Vegfr2Y949F/Y949F and
WT littermates obtained from heterozygote crossings in experiments repeated at
least three times. The Uppsala University board of animal experimentation
approved all animal work; efforts were done to minimize suffering as supervised by
the University veterinarian. Mice were anaesthetized with ketamine/xylazine,
avertin or isoﬂurane (Isoba, 3% induction and 1.5% maintenance).
Statistical analysis. For parametric comparison, Student’s t-test was performed to
compare means between two groups. One-way ANOVAs were performed to
compare 42 treatment groups and two-way ANOVA was used when two factors
were involved, for example, treatment and genotype. Repeated measures ANOVA
was used for tumour growth curves. Multiple comparisons post hoc tests were
chosen based on how many group comparisons were made. When all groups were
compared with each other, Tukey’s Honestly Signiﬁcant Difference (HSD) test was
used, while Sidak’s test was used when individual time points were compared with
each other. Non-parametric Mann–Whitney U-test/Wilcoxon sign-rank test (for
paired comparison) was used to compare two groups, while Kruskal–Wallis test
followed by Dunn’s multiple comparisons was used for 42 group-wise comparisons. GraphPad Prism 6.0 was used for statistical analyses. The threshold for
statistical signiﬁcance was set at a ¼ 0.05 (*Po0.05, **Po0.01 and ***Po0.0001).
Antibodies and growth factors. All antibodies used in this study, their origin and
working concentrations are listed in Supplementary Table 1.
Recombinant mouse VEGFA164 was purchased from Peprotech EC Ltd (Rocky
Hill, NJ, USA) and used for in vitro analyses. Dog VEGFA164, which is 99%
identical to mouse VEGFA, was used for in vivo analyses and was produced at the
Paul-Scherrer Institute, Villigen, Switzerland. In vitro tests showed no difference in
VEGFR2-stimulating activity of commercial mouse VEGF and in-house-produced
dog VEGF. Histamine was from Sigma-Aldrich.
Orthotopic mouse glioma model. Mice (homozygous Vegfr2Y949F/Y949F and WT
littermates) were inoculated with GL261 glioblastoma cells (a kind gift from Geza
Safrany, NRIRR, Budapest). Cells were not veriﬁed but tested negative for
mycoplasma using the Mycoplasma detection kit (Lonza). GL261 is a chemically
induced murine cell line, which when inoculated orthotopically has many features

reminiscent to human glioma18. Cells were cultured in DMEM Glutamax medium
containing 10% FCS, washed and resuspended in PBS for inoculation. Mice were
anaesthetized with isoﬂurane (Isoba, 3% induction and 1.5% maintenance). A small
incision was made rostrocaudally along the midline of the scalp. A small hole was
drilled at stereotaxic coordinates þ 1.1 mm anterior and 2.1 mm lateral to bregma.
A volume of 0.5 ml of cells (1.5  105 cells per ml) were slowly injected using a
Hamilton microsyringe with a 33 G needle at 2.9 mm depth below the dura. The
needle was left in place for 3 min before slow retraction over 2 min. The wound was
closed using 6-0 resorbable suture, and analgesia carprofen (Rimadyl Vet, Orion
Pharma, Sweden; 50 mg per 20 g mouse) was injected subcutaneously on the back.
Tumours were left to grow for 18 days. On the last day, mice were intravenously
injected with 150 mg per 20 g mouse of Alexa-555-Cadaverine (Life Technologies)
together with 100 mg of biotinylated tomato lectin in PBS. After 15 min of
circulation, mice were killed using an overdose of ketamine/xylazine (see above)
and transcardially perfused with physiological saline followed by cold 4%
paraformaldehyde (PFA). Brains were postﬁxed for 4 h and transferred to 25%
sucrose for cryoprotection. Brains were coronally cut on a vibratome at 80 mm
thickness and mounted on cover glass in series to cover the entire volume of the
tumour. Tumour volume was estimated using haematoxylin-and-eosin-stained
sections throughout the brain. Representative sections were immunostained for
lectin (Streptavidine-Alexa-488) and nuclei (Hoechst). The two largest (mid)
sections of each tumour were used for quantiﬁcation of vessel density and
Cadaverine-555 accumulation in the brain, indicating abnormal leakage.
RipTag spontaneous endocrine tumour and metastasis model. Vegfr2Y949F/Y949F
mice were crossed with RIP-Tag2 mice on the C57Bl/6 background.
Vegfr2Y949F/Y949F heterozygous offspring was bred to obtain RIP-Tag2:WT and
RIP-Tag2:Vegfr2Y949F/Y949F homozygous mice. All analyses were done using mice of
mixed gender aged 14 weeks. Islets larger than 1  1 mm were deﬁned as Riptag
tumours, and overtly red islets o1x1 mm were deﬁned as angiogenic islets as
assessed under a stereological microscope. Tumours and pancreas including
angiogenic islets were sectioned and stained to analyse vessel characteristics. For
quantiﬁcation of metastases, right liver lobes were sectioned in their entirety. In all,
30 consecutive sections were examined for score of metastases based on a cluster of at
least 25 cells, which were conﬁrmed by SV40-Tag staining. Average numbers of liver
metastases per section was calculated.
B16F10 subcutaneous primary tumour and metastasis model. B16F10 cells
(American Type Culture Collection) were not validated after purchase but retained
melanin production and were regularly tested negative for mycoplasma using the
Mycoplasma Detection Kit (Lonza). Cells (0.5  106 per 100 ml) were injected subcutaneously in the mouse back skin. Tumour size was measured with a caliper every
other day from D6 and tumours were collected at D12 or D18 after implantation.
Tumour wet and dry weights were measured to determine water content/oedema in
the tumours, calculated (tumour wet weight  tumour dry weight)/tumour wet weight
and given as percentage (%). Tumour vessel characteristics were analysed after
injection of FITC-Lectin (Sigma) in the tail vein, followed by 20-min circulation and
then, a washout with PBS via the left cardiac ventricle. Snap-frozen tumours were
sectioned, stained and imaged using a Zeiss Axioimager. Quantiﬁcation of vessel
parameters was done using ImageJ (National Institutes of Health) in a blinded
fashion. To score for metastatic spread, lentivirus-transduced DsRed-expressing
B16F10 cells (kindly provided by Professor David D. Schlaepfer Department of
Pathology, La Jolla, CA) were injected in the mouse right ear dermis (4  104 cells in
10 ml growth factor-depleted Matrigel; BD). Tumour volume was measured with a
caliper every other day. At D15, mice were perfused with PBS via the left cardiac
ventricle and lungs were removed, ﬁxed and frozen. For quantiﬁcation of metastases,
the left large lung lobe from each mouse was sectioned in its entirety. Lung metastases
were enumerated by counting DsRed-positive lesions from confocal microscopy in
four sections spaced 100 mm apart, in each specimen.
Microsphere extravasation in mouse trachea and Riptag tumours. Twenty
microlitres of 30 nm Fluoro-Max Green Aqueous Fluorescent microspheres (Thermo
Scientiﬁc, Fremont, CA, USA) together with 80 ml solution of VEGFA164 (5 mg per
20 g body weight) or PBS were administered by tail vein injection. Mice were
transcardially perfused using 1% PFA in PBS 1 h later. For histamine-induced
microsphere extravasation, 20 ml of 30 nm ﬂuorescent microspheres was injected
together with histamine solution (80 ml; 1.25 mg per 20 g body weight). Perfusion with
1% PFA was performed after 2 min circulation45. Tracheas were dissected and ﬁxed in
1% PFA in PBS for an additional 2 h, stained with endothelial cell markers to visualize
the vasculature. To observe microsphere extravasation in Riptag tumours, 100 ml of
30-nm ﬂuorescent microspheres was administered by tail vein injection. Intravascular
microspheres were removed by PBS perfusion via the left ventricle 1 h later. Riptag
tumours were postﬁxed in 2% PFA for 6 h and kept in 30% sucrose overnight at 4 °C
followed by embedding in cryosectioning medium. Tumours were sectioned and
stained for endothelial cell markers. Imaging was performed using a Zeiss700 confocal
microscope or a Zeiss 710 Structured Illumination microscope.
TMZ chemotherapy. B16F10 cells (0.5  106 per 100 ml) were injected
subcutaneously in the mouse back skin. From D4 to D8, TMZ dissolved in
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dimethylsulfoxide to a ﬁnal concentration of 2%, was administered i.p. every day at
10 mg kg  1, a dose established to have no effect on B16F10 growth in WT
mice from test studies. Control mice were treated with a similar volume of 2%
dimethylsulfoxide. Tumour size was measured with a caliper every other day from
D6 until D18 after implantation.

samples were incubated with the appropriate secondary antibody for 2 h at room
temperature, and mounted in ﬂuorescent mounting medium (DAKO). Images
were acquired using a Zeiss700 confocal microscope. For analysis of the activation
state of endothelial junctions in the retinal vasculature, the unbiased software
(Matlab)15 was used.

DsRed-expressing B16F10 cell lung colonization. DsRed-expressing B16F10
cells (1 million in 100 ml PBS) were injected into mouse tail vein. At 48 h, mice were
perfused with PBS via the left cardiac ventricle, and lungs were removed, ﬁxed and
frozen. Left lung lobes were sectioned in their entirety. Tumour cell foci were
enumerated by counting DsRed-positive lesions in confocal microscopy in two
sections spaced 400 mm apart and ﬁve ﬁelds per section.

Blood parameter measurements. The blood ﬂow measurements were performed
with a microsphere technique46 as described below: WT and Vegfr2Y949F/Y949F
mice 3–4 months old were anaesthetized with isoﬂurane and placed on an
operating table, where the animal’s body temperature was maintained constant at
38 °C. A polyethylene tracheal tube was inserted to ensure free airways and
polyethylene catheters were inserted into the ascending aorta, via the right carotid
artery, and into the right femoral artery. The former catheter was connected to a
pressure transducer (Physiologic Pressure Transducer; AD Instruments, Oxford,
UK) to allow continuous monitoring of the mean arterial blood pressure, which
was allowed to stabilize for 20–25 min. Approximately 105 microspheres (EZ-Trac;
Triton Technology, San Diego, CA, USA) with a diameter of 10 mm were injected
for 10 s via the catheter with its tip in the ascending aorta. Starting 5 s before the
microsphere injection, and continuing for a total of 60 s, an arterial blood reference
sample was collected by free ﬂow from the catheter in the femoral artery at a rate of
0.10 ml min  1. The exact withdrawal rate in each experiment was conﬁrmed by
weighing the sample.
Arterial blood was then collected from the catheter in the femoral artery and
analysed for blood pH, pCO2, pO2, oxygen saturation, S-HCO3 , base excess,
S-Na þ , S-K þ , haematocrit and haemoglobin concentration, with an iStat (Abbott
Scandinavia). The cassette used for this analysis requires 90 ml of whole blood.
Arterial blood was also used for the determination of blood glucose concentrations
(Medisense Test Reagent Strips; MediSense) and for serum insulin determinations
with ELISA (Rat Insulin ELISA; Mercoedia AB).
The animals were killed, and the organs were carefully dissected free from
fat, blotted and weighed. The microspheres in the organs and the arterial blood
reference sample were visualized by a freeze-thawing technique and counted by
an observer blinded for the origin of the samples47.
The blood ﬂow values were calculated according to the formula
Qorg ¼ Qref  Norg/Nref, where Qorg is organ blood ﬂow (ml min  1), Qref is
withdrawal rate of the reference sample (ml min  1), Norg is the number of
microspheres present in the organ and Nref is the number of microspheres present
in the reference sample46.

Miles assay. Mice (females, 6–8 weeks) were subjected to i.p. injection with pyrilamine maleate salt (4 mg per kg body weight in 0.9% saline, Sigma) to inhibit
unspeciﬁc histamine release (for example, by pulling the skin), 30 min before Evans’
blue tail vein injection (100 ml 1% Evans blue in sterile saline, Sigma).
This was followed by intradermal injection of VEGF (100 ng in 50 ml per site) or
sterile saline 10 min after Evans’ blue administration. Thirty minutes after the VEGF
injection, the dorsal skin was excised and Evans’ blue was extracted by immersion in
formamide buffer. Absorbance at 620 nm was measured using a spectrophotometer
(EMax microplate reader, Molecular Devices, CA, US). Extravasated Evans’ blue was
determined from a standard curve and normalized to tissue weight (g).
Isolation of lung endothelial cells. Mouse lungs were collected at P10 or
3–4 weeks, minced and digested in 10 ml Dulbecco’s PBS medium containing
2 mg ml  1 collagenase type I (Sigma), for 1 h at 37 °C with shaking, followed
by ﬁltration through a 70-mm disposable cell strainer (BD Falcon). Cells were
centrifuged at 400g for 8 min at 4 °C, suspended in cold PBS with 0.1% bovine
serum albumin (BSA) and incubated with anti-rat immunoglobulin G-coated
magnetic beads (Dynabeads sheep anti-Rat IgG, Invitrogen) pre-coupled with rat
anti-mouse platelet/endothelial cell adhesion molecule-1 (PECAM-1; MEC13.3, BD
Pharmingen, 553370) for 10 min, with gentle agitation. Beads were separated from
the solution with a magnetic particle concentrator (Dynal MPC-S, Invitrogen). The
beads were washed ﬁve times with PBS, and endothelial cells were suspended in
MV2 growth medium with the following supplements: 5 ng ml  1 endothelial
growth factor; 0.2 mg ml  1 hydrocortisone; 0.5 ng ml  1 VEGFA; 10 ng ml  1 basic
ﬁbroblast growth factor; 20 ng ml  1 insulin-like growth factor-1 (Promocell); and
5% penicillin/streptomycin (Sigma). The purity of cells was 495% as determined
by staining for VE-cadherin. The isolated lung endothelial cells were cultured on
slides pre-coated with gelatin. Cells were treated with or without 100 ng ml  1
mouse VEGFA164 for 10 min before ﬁxation in 4% PFA in PBS for 10 min,
permeabilized in 0.1% Triton X-100 in PBS for 30 min, followed by immunoﬂuorescent staining. Images were acquired using a Zeiss LSM700 confocal
microscope (  63, numerical aperture 1.4 objectives).
Immunoprecipitation and immunoblotting. For in vitro signal transduction
analyses, endothelial cells were isolated from lungs of P10 pups as described above,
and cultured. Cells were treated with or without 100 ng ml  1 mouse VEGFA164
(PeproTech) for 8 min and lysed for subsequent immunoprecipitation and
immunoblotting.
For in vivo signal transduction analyses, lung lysates were used from mice at 1,
2, 5, 10, 15 or 60 min after injection of dog VEGFA164 in the tail vein. An equal
volume of PBS was injected into control mice. B16F10 tumour lysates were
obtained from mice at D12 or 18 after B16F10 cell implantation. Tissues were lysed
in commercial RIPA buffer (ProteinSimple) followed by immunoprecipitation
for VEGFR2 and immunoblotting, or immunoblotting of total lysates. For
immunoprecipitation, 1.5 mg/ml tissue lysate were diluted in RIPA buffer (20 mM
HEPES, pH 7.5, 150 mM NaCl, 1% NP 40) supplemented with protease inhibitors
(Roche, 04693116001), phosphatase inhibitors (Thermo scientiﬁc, 88667), 1 mM
NaF, 1 mM Na3VO4. Lysates were precleared by incubating with 25 ml of Protein
G Sepharose 4 Fast Flow beads (Ge Healthcare, 17-0618-01) per sample for 2 h at
4 °C. Precleared lysates were incubated with 1.5 mg VEGFR2 antibody for 2 h at
4 °C and 25 ml of Protein G beads were added and incubation continued for 1 h
(lung lysates) and overnight (B16 tumor lysate and isolated lung endothelial cells).
Sepharose beads were washed 5 times with 1 ml RIPA buffer per sample without
protease and phosphatase inhibitors and collected by centrifugation at 3000Xg for
1 min at 4 °C. 30 ml of 2X LDS sample buffer were added to each sample and heat at
70 °C for 10 min. Immunocomplexes were resolved on NuPAGE Novex 4–12% BisTris gels (Invitrogen) and processed for immunoblotting8. Full scans of all
immunoblots are presented in Supplementary Figs 6–13.
Immunoﬂuorescent staining. Eyes were removed and preﬁxed in 4% PFA for
20 min at room temperature. After dissection, retinas were blocked overnight at
4 °C in 1% FBS (Gibco), 3% BSA (Sigma) and 0.5% Triton X-100 (Sigma). Retina
samples were incubated over night with primary antibodies in blocking reagent,
followed by washing and incubation with Isolectin-B4 in Pblec (1 mM MgCl2,
1 mM CaCl2, 0.1 mM MnCl2 and 1% Triton X-100 in PBS) overnight. Thereafter,
14

Blood pressure measurements after VEGF administration. Mice (females,
B15 weeks) were anaesthetized by an intraperitoneal (i.p.) injection of avertin48. A
polyethylene tracheal tube was inserted to ensure free airways, and a polyethylene
catheter was inserted into the descending aorta, via the right femoral artery, and
connected to a pressure transducer (AD Instruments) connected to a PowerLab
system (AD Instruments. When the blood pressure had remained stable for 10 min
an injection of 0.1 ml of saline or VEGFA (5 mg per 20 g body weight) was given in
the right jugular vein. Mean arterial blood pressure was then registered for 15 min.
E11.5 Hindbrain vascularization. Embryos at E11.5 were collected and ﬁxed in 4%
PFA overnight. Hindbrains were dissected the following day and thereafter, brains
were permeabilized in a buffer containing 1% Triton X, 0.01 mM CaCl2, 0.1 mM
MgCl2, 0.1 mM MnCl2, in PBS (pH 6.8), for two 15-min washes and subsequently
incubated with biotinylated isolectin-B4 (L-2140, Sigma-Aldrich, Sweden).
A streptavidine-coupled Alexa-488 (Life Technologies) was used for visualization.
Hindbrains were ﬂat-mounted and imaged in a confocal (LSM700). The image
analysis was done using CellProﬁler (www.cellproﬁler.org) with a pipeline as
follows: an initial segmentation of the vessels was done using a ﬁxed global
threshold, followed by ﬁltering out small particles. Next, a skeleton was computed
from the binary vessel mask. From the skeleton, the number of branch points and
the branch lengths were measured. Branches touching the border or very short
branches were removed. For each branch, the mean distance values for the corresponding skeleton segment were calculated.
Transmission electron microscopy. Two sex- and age-matched mice (7-week-old
male and female Vegfr2Y949F/Y949F and WT littermates) were perfusion ﬁxed
and their organs were collected and embedded in epoxy resin16. Brieﬂy, mice were
anaesthetized using a mixture of ketamine/xylazine and perfused via the left
heart ventricle with oxygenated DMEM/1 mM CaCl2/5 mM D-glucose. This was
immediately followed by perfusion with 3% PFA/1.5% glutaraldehyde/5%
sucrose in 0.1 M phosphate buffer, pH 7.2. Organs (kidney and pancreas) were
removed, cut in small blocks and further ﬁxed (1 h at room temperature) in
2% glutaraldehyde in 0.1 M sodium cacodylate buffer, rinsed in 0.1 M cacodylate,
postﬁxed (1 h, on ice, in the dark) in 1% OsO4, stained (over night, room
temperature, in the dark) with 2% uranyl acetate, dehydrated in graded ethanol and
LX-112 embedded (Ladd Research, Burlington, VT). Ultrathin sections (B30 nm)
were obtained using an oscillating diamond knife (Diatome, Emsdiasum), further
stained with 2% uranyl acetate followed by lead citrate, examined and imaged with
a Jeol 1010 electron microscope using a bottom-mount AMD camera. Images were
exported in TIFF format, and labelled and assembled using Adobe Photoshop and
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Illustrator CS6 (Adobe Systems). In some images, the contrast and brightness were
post-processed in Adobe Photoshop using the respective linear functions.
RNA extraction and sequencing. RNA was extracted using the Qiagen RNeasy kit
following the manufacturer’s instructions and using lungs from 5- to 8-week-old
mice. Extracted RNA quality was assessed with a BioAnalyzer (Agilent Technologies, Wilmington, DE, USA) and concentration estimated using the Qubit RNA
BR Assay Kit (Thermo Ficher Scientiﬁc, Eugene, Oregon, USA). From 11 mg of
total RNA, mRNA puriﬁcation was performed using Dynabeads mRNA
Puriﬁcation Kit (Ambion, Life Technologies AS, Oslo). mRNA libraries, three
biological replicates per sample, were prepared using the Ion Total RNA-Seq Kit v2
(Life Technologies) using the standard protocol, and sequencing was performed on
Ion Proton sequencer (Life Technologies). Libraries were barcoded three per PI v2
chip to achieve 20 million reads per replicate. Reads were processed, mapped to a
reference genome (mm10) and summarized using Torrent Suite version 5.0.2 and
default settings. The statistical analysis of gene expression was performed in R
using DESeq2 package (doi:10.1186/gb-2010-11-10-r106) with dispersion ﬁt type
set to local. The FPKM (fragments per kilobase per million) function from DESeq2
package was used to normalize reads per gene as RPKM (reads per kilobase per
million), using the robust library size estimate. The RPKM values for selected genes
were plotted on the log10 scale based on the folds of our genes of interest established in log2 fold change (log2FC ¼ 1 means the gene is upregulated twofolds).
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